GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longevity Biomedical Inc (NAS:LBIO) » Definitions » ROA %

Longevity Biomedical (Longevity Biomedical) ROA % : 0.00% (As of . 20)


View and export this data going back to 2050. Start your Free Trial

What is Longevity Biomedical ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Longevity Biomedical's annualized Net Income for the quarter that ended in . 20 was $ Mil. Longevity Biomedical's average Total Assets over the quarter that ended in . 20 was $ 0 Mil. Therefore, Longevity Biomedical's annualized ROA % for the quarter that ended in . 20 was Not Available.

The historical rank and industry rank for Longevity Biomedical's ROA % or its related term are showing as below:

LBIO's ROA % is not ranked *
in the Biotechnology industry.
Industry Median: -34.65
* Ranked among companies with meaningful ROA % only.

Longevity Biomedical ROA % Historical Data

The historical data trend for Longevity Biomedical's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Biomedical ROA % Chart

Longevity Biomedical Annual Data
Trend
ROA %

Longevity Biomedical Semi-Annual Data
ROA %

Competitive Comparison of Longevity Biomedical's ROA %

For the Biotechnology subindustry, Longevity Biomedical's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longevity Biomedical's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's ROA % distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's ROA % falls into.



Longevity Biomedical ROA % Calculation

Longevity Biomedical's annualized ROA % for the fiscal year that ended in . 20 is calculated as:

ROA %=Net Income (A: . 20 )/( (Total Assets (A: . 20 )+Total Assets (A: . 20 ))/ count )
=/( (+)/ )
=/
= %

Longevity Biomedical's annualized ROA % for the quarter that ended in . 20 is calculated as:

ROA %=Net Income (Q: . 20 )/( (Total Assets (Q: . 20 )+Total Assets (Q: . 20 ))/ count )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is one times the annual (. 20) net income data. ROA % is displayed in the 30-year financial page.


Longevity Biomedical  (NAS:LBIO) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

Note: The Net Income data used here is one times the annual (. 20) net income data. The Revenue data used here is one times the annual (. 20) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Longevity Biomedical ROA % Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Longevity Biomedical (Longevity Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.

Longevity Biomedical (Longevity Biomedical) Headlines

No Headlines